• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于VHH与MUC1相互作用建模研究的间隔基嵌合T细胞受体构建。

The construction of chimeric T-Cell receptor with spacer base of modeling study of VHH and MUC1 interaction.

作者信息

Pirooznia Nazanin, Hasannia Sadegh, Taghdir Majid, Rahbarizadeh Fatemeh, Eskandani Morteza

机构信息

Department of Biology, Faculty of Science, University of Guilan, Rasht, Iran.

出版信息

J Biomed Biotechnol. 2011;2011:578128. doi: 10.1155/2011/578128. Epub 2011 Aug 22.

DOI:10.1155/2011/578128
PMID:21869862
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3160013/
Abstract

Adaptive cell immunotherapy with the use of chimeric receptors leads to the best and most specific response against tumors. Chimeric receptors consist of a signaling fragment, extracellular spacer, costimulating domain, and an antibody. Antibodies cause immunogenicity; therefore, VHH is a good replacement for ScFv in chimeric receptors. Since peptide sequences have an influence on chimeric receptors, the effect of peptide domains on each other's conformation were investigated. CD3Zeta, CD28, VHH and CD8α, and FcgIIα are used as signaling moieties, costimulating domain, antibody, and spacers, respectively. To investigate the influence of the ligation of spacers on the conformational structure of VHH, models of VHH were constructed. Molecular dynamics simulation was run to study the influence of the presence of spacers on the conformational changes in the binding sites of VHH. Root mean square deviation and root mean square fluctuation of critical segments in the binding site showed no noticeable differences with those in the native VHH. Results from molecular docking revealed that the presence of spacer FcgIIα causes an increasing effect on VHH with MUC1 interaction. Each of the constructs was transformed into the Jurkat E6.1. Expression analysis and evaluation of their functions were examined. The results showed good expression and function.

摘要

使用嵌合受体的适应性细胞免疫疗法可产生针对肿瘤的最佳且最具特异性的反应。嵌合受体由信号片段、细胞外间隔区、共刺激结构域和抗体组成。抗体具有免疫原性;因此,VHH是嵌合受体中ScFv的良好替代物。由于肽序列会影响嵌合受体,因此研究了肽结构域对彼此构象的影响。分别使用CD3Zeta、CD28、VHH和CD8α以及FcgIIα作为信号部分、共刺激结构域、抗体和间隔区。为了研究间隔区连接对VHH构象结构的影响,构建了VHH模型。进行分子动力学模拟以研究间隔区的存在对VHH结合位点构象变化的影响。结合位点关键片段的均方根偏差和均方根波动与天然VHH中的相比没有明显差异。分子对接结果表明,间隔区FcgIIα的存在对VHH与MUC1的相互作用有增强作用。将每个构建体转化到Jurkat E6.1中。检查了它们的表达分析和功能评估。结果显示表达和功能良好。

相似文献

1
The construction of chimeric T-Cell receptor with spacer base of modeling study of VHH and MUC1 interaction.基于VHH与MUC1相互作用建模研究的间隔基嵌合T细胞受体构建。
J Biomed Biotechnol. 2011;2011:578128. doi: 10.1155/2011/578128. Epub 2011 Aug 22.
2
T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.表达VHH导向的寡克隆嵌合HER2抗原受体的T细胞:迈向肿瘤导向的寡克隆T细胞疗法。
Biochim Biophys Acta. 2014 Jan;1840(1):378-86. doi: 10.1016/j.bbagen.2013.09.029. Epub 2013 Sep 27.
3
Molecular characterization of a fully human chimeric T-cell antigen receptor for tumor-associated antigen EpCAM.用于肿瘤相关抗原EpCAM的全人源嵌合T细胞抗原受体的分子特征分析
J Biomed Biotechnol. 2012;2012:853879. doi: 10.1155/2012/853879. Epub 2012 Apr 3.
4
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.一项 I 期临床试验表明,经修饰的抗 MUC1 嵌合抗原受体转导 T 细胞可有效清除 MUC1 阳性转移性精囊癌细胞。
Sci China Life Sci. 2016 Apr;59(4):386-97. doi: 10.1007/s11427-016-5024-7. Epub 2016 Mar 7.
5
Anti-MUC1 nanobody can redirect T-body cytotoxic effector function.抗MUC1纳米抗体可重定向T细胞毒性效应功能。
Hybridoma (Larchmt). 2009 Apr;28(2):85-92. doi: 10.1089/hyb.2008.0079.
6
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.新型含人源可变区的抗 CD19 嵌合抗原受体的功能受铰链和跨膜结构域影响。
Mol Ther. 2017 Nov 1;25(11):2452-2465. doi: 10.1016/j.ymthe.2017.07.013. Epub 2017 Jul 27.
7
Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.嵌合受体可从单一基因产物为T细胞提供主要信号和共刺激信号。
J Immunol. 1998 Sep 15;161(6):2791-7.
8
Delicate balance among thermal stability, binding affinity, and conformational space explored by single-domain VH antibodies.单域 VH 抗体探索热稳定性、结合亲和力和构象空间之间的微妙平衡。
Sci Rep. 2021 Oct 18;11(1):20624. doi: 10.1038/s41598-021-98977-8.
9
Anti-peptide antibodies detect conformational changes of the inter-SH2 domain of ZAP-70 due to binding to the zeta chain and to intramolecular interactions.抗肽抗体可检测ZAP-70分子内SH2结构域因与ζ链结合及分子内相互作用而发生的构象变化。
J Biol Chem. 1998 Apr 10;273(15):8916-21. doi: 10.1074/jbc.273.15.8916.
10
A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.嵌合T细胞受体组件的单链抗体与CD3 ζ链结构域之间的间隔区是有效配体结合和信号传导活性所必需的。
Gene Ther. 1995 Oct;2(8):539-46.

引用本文的文献

1
Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy.嵌合抗原受体工程化细胞免疫疗法的当前挑战与新出现的机遇
Exp Hematol Oncol. 2025 Jul 2;14(1):92. doi: 10.1186/s40164-025-00683-y.
2
A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers.一种表达靶向CD25的新型嵌合抗原受体自然杀伤细胞,有望克服癌症中的免疫逃逸机制。
Front Oncol. 2021 May 14;11:649710. doi: 10.3389/fonc.2021.649710. eCollection 2021.
3
Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy.

本文引用的文献

1
Anti-MUC1 nanobody can redirect T-body cytotoxic effector function.抗MUC1纳米抗体可重定向T细胞毒性效应功能。
Hybridoma (Larchmt). 2009 Apr;28(2):85-92. doi: 10.1089/hyb.2008.0079.
2
The T-body approach: redirecting T cells with antibody specificity.T 细胞体方法:利用抗体特异性重定向 T 细胞。
Handb Exp Pharmacol. 2008(181):329-42. doi: 10.1007/978-3-540-73259-4_14.
3
Adoptive T cell therapy for cancer in the clinic.临床上用于癌症治疗的过继性T细胞疗法。
基于单域抗体的 TCR 样 CAR-T:一种潜在的癌症治疗方法。
J Immunol Res. 2020 Sep 7;2020:2454907. doi: 10.1155/2020/2454907. eCollection 2020.
J Clin Invest. 2007 Jun;117(6):1466-76. doi: 10.1172/JCI32446.
4
MUC1 is a promising therapeutic target for prostate cancer therapy.黏蛋白1是前列腺癌治疗中一个很有前景的治疗靶点。
Curr Cancer Drug Targets. 2007 May;7(3):259-71. doi: 10.2174/156800907780618338.
5
Principles of adoptive T cell cancer therapy.过继性T细胞癌症治疗的原则。
J Clin Invest. 2007 May;117(5):1204-12. doi: 10.1172/JCI31446.
6
Antitumor activity of dual-specific T cells and influenza virus.双特异性T细胞和流感病毒的抗肿瘤活性。
Cancer Gene Ther. 2007 May;14(5):499-508. doi: 10.1038/sj.cgt.7701034. Epub 2007 Mar 2.
7
Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy.共刺激调节过继性免疫治疗中重定向T细胞的肿瘤特异性激活。
Cancer Immunol Immunother. 2007 May;56(5):731-7. doi: 10.1007/s00262-006-0249-0. Epub 2006 Dec 2.
8
Adoptive T-cell therapy of cancer.癌症的过继性T细胞疗法。
Hematol Oncol Clin North Am. 2006 Jun;20(3):711-33. doi: 10.1016/j.hoc.2006.02.008.
9
Adoptive T-cell transfer in cancer immunotherapy.癌症免疫治疗中的过继性T细胞转移
Immunol Cell Biol. 2006 Jun;84(3):281-9. doi: 10.1111/j.1440-1711.2006.01441.x.
10
Prospects and limitations of T cell receptor gene therapy.T细胞受体基因治疗的前景与局限
Curr Gene Ther. 2005 Dec;5(6):583-93. doi: 10.2174/156652305774964730.